首頁 › 非霍奇金淋巴瘤 › 俄亥俄州 › Cleveland
Cleveland, OH 的 非霍奇金淋巴瘤 臨床試驗
13 項針對 非霍奇金淋巴瘤 的研究正在 Cleveland（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
招募中1/2 期
- University Hospitals Seidman Cancer Center, Cleveland
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- Cleveland Clinic, Cleveland
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
招募中1 期
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
招募中1 期
- Clinical Trial Site, Cleveland
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Cleveland Clinic, Cleveland
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- Cleveland Clinical Taussig Cancer Center, Cleveland
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中觀察性研究
- University Hospitals Case Medical Center, Cleveland
- Cleveland Clinic, Cleveland
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
招募中1 期
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Mayfield Heights · 距離 12 英里
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- University Hospitals Cleveland Medical Center, Cleveland
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
招募中1/2 期
- University Hospitals Cleveland, Cleveland
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
招募中1 期
- University Hospitals Seidman Cancer Center, Cleveland
- Taussig Cancer Institute | Cleveland Clinic, Cleveland
其他城市的 非霍奇金淋巴瘤 試驗
- Houston, TX31 項研究
- New York City, NY31 項研究
- Boston, MA26 項研究
- Nashville, TN21 項研究
- Philadelphia, PA20 項研究
- Baldwin Park, CA19 項研究
- Washington, DC18 項研究
- Chicago, IL18 項研究
- Milwaukee, WI18 項研究
- Atlanta, GA18 項研究
- Columbus, OH18 項研究
- Dallas, TX17 項研究
Cleveland 的其他研究
- 非小細胞肺癌43 項研究
- 癌症（所有類型）36 項研究
- 乳癌35 項研究
- 前列腺癌34 項研究
- 心臟衰竭33 項研究
- 卵巢癌30 項研究
- 轉移性癌症30 項研究
- 肺癌26 項研究
- 大腸直腸癌24 項研究
- 心血管疾病22 項研究
- 子宮內膜癌20 項研究
- 急性髓系白血病20 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。